[go: up one dir, main page]

DK1420759T3 - Farmaceutiske sammensætninger til behandling af astma - Google Patents

Farmaceutiske sammensætninger til behandling af astma

Info

Publication number
DK1420759T3
DK1420759T3 DK02753549T DK02753549T DK1420759T3 DK 1420759 T3 DK1420759 T3 DK 1420759T3 DK 02753549 T DK02753549 T DK 02753549T DK 02753549 T DK02753549 T DK 02753549T DK 1420759 T3 DK1420759 T3 DK 1420759T3
Authority
DK
Denmark
Prior art keywords
asthma
treatment
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
DK02753549T
Other languages
English (en)
Inventor
Joel A Sequeira
Stefan A Sharpe
John L Hart
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23224164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1420759(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1420759T3 publication Critical patent/DK1420759T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02753549T 2001-08-28 2002-08-27 Farmaceutiske sammensætninger til behandling af astma DK1420759T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31538601P 2001-08-28 2001-08-28
PCT/US2002/027336 WO2003020253A2 (en) 2001-08-28 2002-08-27 Pharmaceutical compositions for the treatment of asthma

Publications (1)

Publication Number Publication Date
DK1420759T3 true DK1420759T3 (da) 2009-08-03

Family

ID=23224164

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02753549T DK1420759T3 (da) 2001-08-28 2002-08-27 Farmaceutiske sammensætninger til behandling af astma
DK09006110.2T DK2092935T3 (da) 2001-08-28 2002-08-27 Farmaceutiske sammensætninger til behandling astma

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09006110.2T DK2092935T3 (da) 2001-08-28 2002-08-27 Farmaceutiske sammensætninger til behandling astma

Country Status (26)

Country Link
US (3) US20030114428A1 (da)
EP (3) EP1420759B1 (da)
JP (3) JP2005502675A (da)
KR (1) KR100970531B1 (da)
CN (2) CN101856362A (da)
AR (1) AR036358A1 (da)
AT (2) ATE430555T1 (da)
AU (1) AU2002313828B2 (da)
BR (1) BR0212089A (da)
CA (1) CA2457926A1 (da)
CO (1) CO5560551A2 (da)
CY (2) CY1109212T1 (da)
DE (2) DE60239648D1 (da)
DK (2) DK1420759T3 (da)
ES (3) ES2325316T3 (da)
HU (1) HUP0401514A3 (da)
MX (1) MXPA04001875A (da)
NO (1) NO20041277L (da)
NZ (1) NZ530987A (da)
PE (1) PE20030390A1 (da)
PL (1) PL209640B1 (da)
PT (2) PT1420759E (da)
SI (2) SI1420759T1 (da)
TW (1) TWI324934B (da)
WO (1) WO2003020253A2 (da)
ZA (1) ZA200401419B (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
RO121172B1 (ro) * 2001-03-30 2007-01-30 Jago Research Ag Compoziţie farmaceutică de aerosol şi utilizarea acesteia
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1785156B1 (en) * 2002-08-23 2012-06-27 Schering Corporation Metered dose inhaler containing an aerosol suspension formulation
EP1542753B1 (en) * 2002-08-23 2007-02-07 Schering Corporation Pharmaceutical compositions
CA2495875C (en) * 2002-08-27 2010-06-22 Schering Corporation Process for producing metered dose inhaler formulations
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
CA2542530A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical aerosol compositions
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
RS51335B (sr) * 2004-01-21 2011-02-28 Schering Corporation Metoda lečenja akutnog rinosinusitisa
US20110053999A1 (en) * 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
DE602005009012D1 (de) * 2004-10-12 2008-09-25 Generics Uk Ltd Rmulierungen, worin die partikel durch präzipition in einem aerosolbehälter gebildet werden
CA2603433A1 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
US20070203104A1 (en) * 2006-02-09 2007-08-30 Chaudhry Saeed M Pharmaceutical Formulations
BRPI0721256A2 (pt) * 2007-02-09 2013-03-12 Schering Corp aerossàis de fÁrmaco farmacÊuticos estÁveis
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
CA2711292A1 (en) * 2008-01-10 2009-07-16 Schering Corporation Inhalation drug products, systems and uses
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
JP5763053B2 (ja) 2009-05-18 2015-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アダプタ、吸入器具及びアトマイザ
EP2435025B1 (en) * 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
AP3141A (en) 2009-11-25 2015-02-28 Boehringer Ingelheim Int Nebulizer
EP2504051B1 (en) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
US9173850B2 (en) * 2009-12-07 2015-11-03 Raptor Pharmaceuticals Inc. 4-methylpyrazole formulations
PH12012501666A1 (en) 2010-02-22 2012-11-05 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - betamethasone dipropionate, and a process to make it
WO2011101830A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
WO2012017368A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2012049543A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
TR201903199T4 (tr) * 2011-10-11 2019-03-21 Chiesi Farm Spa Bir yağ asidiyle kaplı bir beta agonistin kristal mikropartikülleri.
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
US9744313B2 (en) 2013-08-09 2017-08-29 Boehringer Ingelheim International Gmbh Nebulizer
ES2874029T3 (es) 2014-05-07 2021-11-04 Boehringer Ingelheim Int Nebulizador
PE20210959A1 (es) 2014-05-07 2021-05-25 Boehringer Ingelheim Int Nebulizador, dispositivo indicador y recipiente
CN106255554B (zh) 2014-05-07 2021-05-04 勃林格殷格翰国际有限公司 容器、喷雾器及用途
JP6564407B2 (ja) 2014-06-30 2019-08-21 プロヴェリス・サイエンティフィック・コーポレイション 薬物の送達用量の量及び均一性を確定するための試料採取機器及び関連方法
EP3383366B2 (en) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2017156287A1 (en) * 2016-03-09 2017-09-14 Proveris Scientific Corporation Methods for measuring dose content uniformity performance of inhaler and nasal devices
CN106619658B (zh) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 一种医用气溶胶制剂及定量吸入气雾剂
WO2021219495A1 (en) 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
ATE134509T1 (de) * 1991-06-10 1996-03-15 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
EE9700138A (et) * 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
ES2159148T3 (es) * 1996-08-29 2001-09-16 Schering Corp Formulaciones en aerosol de furoato de mometasona libres de clorofluorocarbonos.
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
GB2359749B (en) * 1998-11-26 2004-05-05 Britannia Pharmaceuticals Ltd Anti-asthmatic combinations comprising surface active phospholipids
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
MXPA02007052A (es) * 2000-01-20 2002-12-13 Basilea Pharmaceutica Ag Composiciones que se administran nasalmente y que contienen peptidos ciclicos.
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
AU2001278115A1 (en) * 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme

Also Published As

Publication number Publication date
JP5170789B2 (ja) 2013-03-27
EP1420759A2 (en) 2004-05-26
PT2092935E (pt) 2011-05-31
AR036358A1 (es) 2004-09-01
ATE430555T1 (de) 2009-05-15
CY1111726T1 (el) 2015-10-07
TWI324934B (en) 2010-05-21
ATE503461T1 (de) 2011-04-15
HUP0401514A3 (en) 2012-08-28
PE20030390A1 (es) 2003-04-24
ES2361805T3 (es) 2011-06-22
EP2319494A1 (en) 2011-05-11
CO5560551A2 (es) 2005-09-30
HK1060972A1 (en) 2004-09-03
AU2002313828B2 (en) 2005-09-08
DK2092935T3 (da) 2011-07-18
KR20040031002A (ko) 2004-04-09
US20030114428A1 (en) 2003-06-19
DE60232251D1 (de) 2009-06-18
PL209640B1 (pl) 2011-09-30
HUP0401514A2 (hu) 2004-12-28
US20050147565A1 (en) 2005-07-07
ES2389480T3 (es) 2012-10-26
EP2319494B1 (en) 2012-06-13
PL368897A1 (en) 2005-04-04
HK1151987A1 (en) 2012-02-17
EP2092935B1 (en) 2011-03-30
MXPA04001875A (es) 2004-06-15
HK1128428A1 (en) 2009-10-30
DE60239648D1 (de) 2011-05-12
KR100970531B1 (ko) 2010-07-16
CA2457926A1 (en) 2003-03-13
ES2325316T3 (es) 2009-09-01
JP2005502675A (ja) 2005-01-27
CN1649568A (zh) 2005-08-03
NZ530987A (en) 2006-08-31
CY1109212T1 (el) 2014-07-02
NO20041277L (no) 2004-03-26
EP2092935A1 (en) 2009-08-26
SI1420759T1 (sl) 2009-10-31
JP2010138184A (ja) 2010-06-24
JP2009185075A (ja) 2009-08-20
PT1420759E (pt) 2009-06-30
CN1649568B (zh) 2010-10-27
WO2003020253A2 (en) 2003-03-13
WO2003020253A3 (en) 2003-05-22
SI2092935T1 (sl) 2011-07-29
CN101856362A (zh) 2010-10-13
EP1420759B1 (en) 2009-05-06
US20100143269A1 (en) 2010-06-10
BR0212089A (pt) 2004-08-03
ZA200401419B (en) 2005-01-26

Similar Documents

Publication Publication Date Title
DK1420759T3 (da) Farmaceutiske sammensætninger til behandling af astma
DK1425001T3 (da) Phenethanolaminderivater til behandling af respiratoriske sygdomme
FI20011478L (fi) Farmaseuttinen koostumus
EP1466610A4 (en) MEDICAL COMPOSITIONS FOR RECEIVING VIA THE NOSE
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
DK1353668T3 (da) Fremgangsmåder til fremstillingen af farmaceutiske sammensætninger, der indeholder epothilonanaloger, til behandlingen af cancer
DK1450606T3 (da) Synergistiske sammensætninger til behandling af såsæd
DK1381351T3 (da) Fremgangsmåde til kontinuerlig fremstilling af inhalerbare medikamenter
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
IS7051A (is) Lyfjasamsetningar
EE200300537A (et) Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks
DK1478438T3 (da) Fremgangsmåder og sammensætninger til behandling af astma
FI20022128A0 (fi) Farmaseuttinen koostumus
NO20034556L (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
DK1344526T3 (da) Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
DK1475379T3 (da) Anvendelse af scopinesterderivater til fremstilling af lægemidler
FI20010892A0 (fi) Menetelmä ksylitolin valmistamiseksi
DK1451177T3 (da) Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne
PT1372636E (pt) Dosagem metronomica para taxanos
DK2105135T3 (da) Farmaceutiske sammensætninger til behandling af cancer
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
EP1413314A4 (en) MEDICAL COMPOSITIONS
ITRM20030442A0 (it) Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia.